Gladstone Institutional Advisory
GPCR icon

Gladstone Institutional Advisory’s Structure Therapeutics GPCR Stock Holding History

Gladstone Institutional Advisory’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$378K Sell
12,075
-1,200
-9% -$56.3K 0.01% 738
2026
Q2 		$712K Buy
+13,275
New +$587K 0.02% 497

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Capitolis Liquid Global Markets
Capitolis Liquid Global Markets New York $22.4B AUM 40.52% 1-Year Est. Return
Pacific Heights Asset Management
Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
NEXTBio Capital Management
NEXTBio Capital Management Menlo Park, California $234M AUM 176.49% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Gladstone Institutional Advisory's GPCR Position: Q3 2026 in Review

Gladstone Institutional Advisory reduced its Structure Therapeutics (GPCR) stake by 9% in Q3 2026, selling an estimated $56.3K and leaving 12,075 shares worth $378K. The position accounts for 0.01% of the portfolio, ranked #738.

Gladstone Institutional Advisory first reported a position in GPCR in Q2 2026 and has held it in 2 quarters since. The position peaked at $712K in Q2 2026. 102 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Gladstone Institutional Advisory held 12,075 shares of Structure Therapeutics worth $378K as of Q3 2026.
  • Gladstone Institutional Advisory sold 1,200 Structure Therapeutics shares in Q3 2026, an estimated $56.3K.
  • Structure Therapeutics made up 0.01% of Gladstone Institutional Advisory's portfolio in Q3 2026, its #738 holding.
  • Gladstone Institutional Advisory first reported a position in Structure Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Gladstone Institutional Advisory's Structure Therapeutics position peaked at $712K in Q2 2026.
  • 102 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q3 2026, filed 13 Nov 2026.